Abstract
Alzheimers Dement. 2026 Nov;22(11):e72021. doi: 10.1002/alz.72021.
ABSTRACT
INTRODUCTION: Alzheimer's disease (AD) co-pathology is common in dementia with Lewy bodies (DLB) and has been linked to worse clinical outcomes. Whether AD biomarker status influences cognitive trajectories and treatment-associated cognitive trajectories in DLB remains unclear.
METHODS: We conducted a retrospective cohort study by linking the Swedish Registry for Cognitive/Dementia Disorders (SveDem) with cerebrospinal fluid (CSF) biomarker data. Participants were individuals with incident DLB diagnosed between 2010 and 2020 who had CSF amyloid-β42/amyloid-β40 (Aβ42/40) or Aβ42/phosphorylated tau (p-tau) measurements and longitudinal Mini-Mental State Examination (MMSE) assessments during follow-up. Linear mixed-effects models incorporating inverse probability of treatment and censoring weighting estimated cognitive trajectories according to AD biomarker status and antidementia treatment.
RESULTS: Among 360 participants (mean age 73.3 years; 33.9% women), 196 (54.4%) were AD biomarker-positive. AD biomarker-positive participants exhibited faster cognitive decline than biomarker-negative participants, with an additional decline of 0.80 MMSE points per year (95% confidence interval [CI], -1.17 to -0.43). Overall, cholinesterase inhibitor (ChEI) use was associated with slower cognitive decline than no treatment, whereas associations for memantine were less consistent. In biomarker-stratified analyses, ChEI use was associated with slower decline among AD biomarker-positive participants but not among biomarker-negative participants. Formal interaction analyses indicated that treatment-associated differences in MMSE change varied according to AD biomarker status.
DISCUSSION: AD biomarker positivity identifies a subgroup of individuals with DLB at higher risk of accelerated cognitive decline. Treatment-associated cognitive trajectories also differed according to AD biomarker status; however, these observational treatment findings require cautious interpretation and confirmation in prospective biomarker-stratified studies.
PMID:43059509 | DOI:10.1002/alz.72021
UK DRI Authors